
Johannes P Langedijk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1805469/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. Science, 2011, 333, 850-856.	12.6	1,092
2	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586, 583-588.	27.8	765
3	Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE, 2010, 5, e8805.	2.5	405
4	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. Npj Vaccines, 2020, 5, 91.	6.0	286
5	A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature Communications, 2015, 6, 8143.	12.8	248
6	Stabilizing the closed SARS-CoV-2 spike trimer. Nature Communications, 2021, 12, 244.	12.8	139
7	Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nature Chemical Biology, 2016, 12, 87-93.	8.0	121
8	A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. Cell Reports, 2018, 23, 584-595.	6.4	93
9	Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis. Journal of Virology, 2003, 77, 12067-12073.	3.4	85
10	Measles Virus (MV) Hemagglutinin: Evidence that Attachment Sites for MV Receptors SLAM and CD46 Overlap on the Globular Head. Journal of Virology, 2004, 78, 9051-9063.	3.4	79
11	Structural and Functional Relationship between the Receptor Recognition and Neuraminidase Activities of the Newcastle Disease Virus Hemagglutinin-Neuraminidase Protein: Receptor Recognition Is Dependent on Neuraminidase Activity. Journal of Virology, 2001, 75, 1918-1927.	3.4	77
12	Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants. Journal of Virology, 2008, 82, 6678-6688.	3.4	76
13	Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors. Journal of Biological Chemistry, 2009, 284, 26941-26950.	3.4	71
14	Transient opening of trimeric prefusion RSV F proteins. Nature Communications, 2019, 10, 2105.	12.8	71
15	Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function. Journal of Virology, 2011, 85, 10785-10797.	3.4	66
16	A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition. PLoS Pathogens, 2013, 9, e1003202.	4.7	64
17	Structural Rearrangements of the Central Region of the Morbillivirus Attachment Protein Stalk Domain Trigger F Protein Refolding for Membrane Fusion. Journal of Biological Chemistry, 2012, 287, 16324-16334.	3.4	63
18	Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nature Communications, 2017, 8, 167.	12.8	58

#	Article	IF	CITATIONS
19	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV,the, 2020, 7, e688-e698.	4.7	58
20	Translocation Activity of C-terminal Domain of Pestivirus Erns and Ribotoxin L3 Loop. Journal of Biological Chemistry, 2002, 277, 5308-5314.	3.4	57
21	Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies. PLoS Pathogens, 2018, 14, e1006935.	4.7	50
22	Evidence of a Potential Receptor-Binding Site on the Nipah Virus G Protein (NiV-G): Identification of Globular Head Residues with a Role in Fusion Promotion and Their Localization on an NiV-G Structural Model. Journal of Virology, 2006, 80, 7546-7554.	3.4	47
23	Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Cell Reports, 2020, 30, 4540-4550.e3.	6.4	46
24	Solution Structure of the Immunodominant Region of Protein G of Bovine Respiratory Syncytial Virusâ€,‡. Biochemistry, 1996, 35, 14684-14688.	2.5	38
25	Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. Npj Vaccines, 2021, 6, 39.	6.0	38
26	Novel Strategy for Inhibiting Viral Entry by Use of a Cellular Receptor-Plant Virus Chimera. Journal of Virology, 2002, 76, 4412-4419.	3.4	35
27	Sequential Conformational Changes in the Morbillivirus Attachment Protein Initiate the Membrane Fusion Process. PLoS Pathogens, 2015, 11, e1004880.	4.7	35
28	Identification of Key Residues in Virulent Canine Distemper Virus Hemagglutinin That Control CD150/SLAM-Binding Activity. Journal of Virology, 2010, 84, 9618-9624.	3.4	32
29	Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. Cell Reports, 2020, 33, 108432.	6.4	32
30	Canine Distemper Virus Infects Canine Keratinocytes and Immune Cells by Using Overlapping and Distinct Regions Located on One Side of the Attachment Protein. Journal of Virology, 2011, 85, 11242-11254.	3.4	31
31	Epitope Mapping of Broadly Neutralizing HIV-2 Human Monoclonal Antibodies. Journal of Virology, 2012, 86, 12115-12128.	3.4	27
32	An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Analytical Biochemistry, 2004, 333, 372-380.	2.4	25
33	HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. Journal of Biological Chemistry, 2019, 294, 5736-5746.	3.4	24
34	Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. Npj Vaccines, 2020, 5, 49.	6.0	24
35	A Hidden Region in the Third Variable Domain of HIV-1 IIIB gp120 Identified by a Monoclonal Antibody. AIDS Research and Human Retroviruses, 1993, 9, 605-612.	1.1	23
36	Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. Neurobiology of Disease, 2005, 19, 273-282.	4.4	21

JOHANNES P LANGEDIJK

#	Article	IF	CITATIONS
37	HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. Journal of Virology, 2016, 90, 10587-10599.	3.4	18
38	Identification of Amino Acid Substitutions with Compensational Effects in the Attachment Protein of Canine Distemper Virus. Journal of Virology, 2014, 88, 8057-8064.	3.4	17
39	Peptide mimetics of immunoglobulin A (IgA) and FcαRI block IgAâ€induced human neutrophil activation and migration. European Journal of Immunology, 2017, 47, 1835-1845.	2.9	16
40	SUMO Assay with Peptide Arrays on Solid Support: Insights into SUMO Target Sites. Journal of Biochemistry, 2008, 144, 39-49.	1.7	12
41	Helical peptide arrays for lead identification and interaction site mapping. Analytical Biochemistry, 2011, 417, 149-155.	2.4	11
42	Peptides based on the presenilinâ€APP binding domain inhibit APP processing and Aβ production through interfering with the APP transmembrane domain. FASEB Journal, 2012, 26, 3765-3778.	0.5	11
43	Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor. Virus Research, 2019, 259, 28-37.	2.2	10
44	Structure-Based Design for High-Hanging Vaccine Fruits. Advances in Immunology, 2012, 114, 33-50.	2.2	7
45	Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	7
46	Heterologous Stacking of Prion Protein Peptides Reveals Structural Details of Fibrils and Facilitates Complete Inhibition of Fibril Growth. Journal of Biological Chemistry, 2009, 284, 12809-12820.	3.4	5
47	Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 205-219.	3.0	3
48	A sweet surprise for HIV broadly neutralizing antibodies. Nature Medicine, 2012, 18, 1616-1617.	30.7	3